Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2021-10-08 Audit Report / Informat…
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
Oxurion - Special report BoD EGM 20211109 (7-228 BCCA)tg.pdf
Audit Report / Information Classification · 95% confidence The document is explicitly titled "SPECIAL REPORT IN ACCORDANCE WITH ARTICLE 7:228 OF THE BELGIAN COMPANIES AND ASSOCIATIONS CODE". This article mandates a special report to the general shareholders' meeting when net assets fall below one quarter of the share capital, requiring a decision on dissolution or continuity measures. The content details the financial situation (as of Dec 31, 2020, and June 30, 2021) that triggered this requirement and proposes a resolution to continue operations, referencing a financing agreement. This type of mandatory, specific report detailing financial distress procedures and proposed resolutions to shareholders aligns best with the 'Audit Report / Information' (AR) category, as it is a formal report on the company's financial health and required statutory response, distinct from a full Annual Report (10-K) or a simple Earnings Release (ER). It is a formal statutory report. H1 2021
2021-10-08 Dutch
Convocation of extraordinary shareholders' meeting on 9 november 2021 (EN).pdf
AGM Information Classification · 99% confidence The document is explicitly titled 'CONVOCATION OF THE SPECIAL SHAREHOLDERS' MEETING' and details the agenda, proposed resolutions, voting procedures, and admission requirements for a meeting scheduled for November 9, 2021. This content directly relates to the formal process and materials surrounding a general shareholders' meeting. This aligns perfectly with the definition of 'AGM Information' (AGM-R), even though it is a 'Special' meeting, as it concerns the formal gathering of shareholders for corporate decisions.
2021-10-08 English
Oproeping BAV 9 november 2021 (NL).pdf
AGM Information Classification · 100% confidence The document is explicitly titled "OPROEPING TOT BIJZONDERE ALGEMENE VERGADERING" (Call for an Extraordinary General Meeting). It details the date, time, agenda items (including board confirmation, continuity measures, and financing), voting procedures, and conditions for participation (registration date, notification of intent to attend, remote voting via proxy/mail). This content perfectly matches the definition of materials shared for an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM). Therefore, the appropriate classification is AGM-R.
2021-10-08 Dutch
XURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)
Regulatory Filings Classification · 95% confidence The document is explicitly titled "**PRESS RELEASE**" and contains the header "*Regulated Information – Inside Information*". It announces positive results from a clinical study (Phase 2, Part A of KALAHARI) for a drug candidate (THR-149) and details the decision to move into Part B. This structure—a formal announcement of material, non-public information regarding clinical trial progress—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing specific operational/clinical milestones rather than comprehensive financial results (which would be an ER or IR), and it is not a short announcement linking to a full report (ruling out RPA), it fits best as a general announcement of material information. Given the options, 'ER' (Earnings Release) is often used broadly for period results announcements, but this is a clinical update. 'RNS' (Regulatory Filings) is the best fallback for material, non-financial regulatory announcements that don't fit other specific categories like DIRS, DIV, or CAP. However, because it details key operational/clinical progress and is a formal press release, it often functions similarly to an Earnings Release in terms of market impact, even if the content is clinical. Since it is a detailed announcement of clinical progress and future plans, and not just a brief notice, I will classify it as an Earnings Release (ER) as it serves the function of reporting period-specific operational performance/milestones, or RNS. Given the focus on clinical trial results and moving to the next phase, it is a significant operational update. I will lean towards RNS as the most accurate catch-all for material, non-financial regulatory news that isn't a standard financial report or a specific event announcement.
2021-09-30 English
OXUR HY BU 2021 (NL) 09092021 FINAL.pdf
Earnings Release Classification · 99% confidence The document is titled "Oxurion NV Business- en financiële update - H1 2021" and explicitly states it publishes its "business- and financial update for the period of six months ended June 30, 2021." This content, which includes detailed clinical trial updates (THR-149, THR-687), corporate changes (CEO promotion, restructuring), and financial position (€10 million cash, financing commitments), is characteristic of a comprehensive report covering a period shorter than a full year (six months). This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a brief announcement (RPA/ER) as it contains substantial detail, nor is it the full Annual Report (10-K). H1 2021
2021-09-09 Dutch
Oxurion - Special Board report Negma ENG.pdf
Capital/Financing Update Classification · 98% confidence The document is titled "SPECIAL REPORT OF THE BOARD OF DIRECTORS IN ACCORDANCE WITH ARTICLE 7:198 JUNCTO ARTICLES 7:180, 7:191 AND 7:193 OF THE BELGIAN CODE OF COMPANIES AND ASSOCIATIONS". It details a proposed transaction involving the issue of Convertible Bonds (CBs) and the cancellation of preferential subscription rights to a specified person (Negma Group Ltd.). This structure—a detailed report from the Board of Directors justifying a specific corporate action, particularly one involving capital structure changes and the cancellation of shareholder rights under specific articles of the Belgian Code of Companies and Associations—strongly indicates a document related to capital structure changes and financing activities, often required to be presented to shareholders or regulators for approval. It discusses the issuance of bonds (a financing activity) and the cancellation of subscription rights (a capital change). This aligns best with the 'Capital/Financing Update' (CAP) category, as it is a detailed report justifying a specific financing/capital event, rather than a general annual report (10-K) or a simple announcement of a dividend (DIV) or share repurchase (POS). It is not a general Audit Report (AR) or a standard Investor Presentation (IP), but a specific statutory report concerning a capital transaction.
2021-09-09 Dutch

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.